From GlobeNewswire:

PROCEPT BioRobotics Corporation reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023.Total revenue for the fourth quarter of 2023 is expected to be in the range of $43.3 million to $43.6 million, compared to $23.8 million in the prior year period. The fiscal year 2023 revenue is expected to be approximately $135.9 million to $136.2 million, representing growth of approximately 81% to 82% compared to the prior year period. The Company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results for the fourth quarter and fiscal year 2023. Investors interested in listening to the conference call may do so by following the provided links, and live audio will be available on the “Investors” section of the Company’s website. PROCEPT BioRobotics is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures, and sells the AquaBeam Robotic System for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to BPH. They have developed a significant and growing body of clinical evidence supporting the benefits and clinical advantages of Aquablation therapy. PROCEPT BioRobotics advises potential customers that all surgical treatments have inherent and associated side effects and investors can contact Matt Bacso, VP of Investor Relations and Business Operations by email for more information.



Read more: PROCEPT BioRobotics® Announces Preliminary Fourth Quarter